EmPower Clinic Services, L.L.C.

EmPower Clinic Services, L.L.C., commonly known as Empower Pharmacy or Empower Pharma, is a private compounding pharmacy headquartered in Houston, Texas, with operations also in East Windsor, New Jersey. The company has shown significant growth in its workforce, employing 1,138 individuals in 2025, an increase from 912 in 2024 and 691 in 2023.

Empower Pharmacy operates as a PCAB®-accredited 503A compounding pharmacy and a 503B outsourcing facility, focusing on expanding access to quality, affordable medication. They specialize in personalized healthcare solutions, including patient-specific compounded medications and bulk manufacturing for office use. Their offerings encompass sterile injectable formulations, topical and dermatological compounds, oral dosage forms, and longevity-focused small-molecule and peptide formulations, targeting areas such as hormone replacement, weight management, and dermatology.

In terms of patent litigation, EmPower Clinic Services, L.L.C. appears as a plaintiff in one tracked case before the Patent Trial and Appeal Board (PTAB). This posture indicates an active role in challenging patent validity. The company has no tracked defendant cases in this specific database. However, it's important to note that EmPower Clinic Services, L.L.C. is also a defendant in other disputes, including trademark and state law claims filed by Eli Lilly and Company, primarily concerning the production of compounded tirzepatide drugs.

The notable tracked case, EmPower Clinic Services, L.L.C. v. Eli Lilly & Co. (IPR2025-01024), was filed on May 22, 2025, at the PTAB. In this inter partes review, Empower is petitioning to invalidate claims of Eli Lilly's U.S. Patent No. 9,474,780, which covers GIP/GLP-1 Receptor Co-agonist Peptide Compounds relevant to drugs like tirzepatide. Empower argues that the challenged patent claims are unpatentable due to obviousness over existing prior art. This PTAB action is part of a broader legal landscape where Eli Lilly has also pursued litigation against Empower regarding compounded versions of its medications. The FDA has additionally issued warning letters to Empower concerning deficiencies in drug product production and insanitary conditions.